Institute of Cancer and Genomic Sciences, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.
Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University, Oxford, Oxfordshire, UK.
J Med Genet. 2022 Jan;59(1):65-74. doi: 10.1136/jmedgenet-2020-107257. Epub 2021 May 18.
Wolfram syndrome (WFS) is a rare disorder characterised by childhood-onset diabetes mellitus and progressive optic atrophy. Most patients have variants in the gene. We undertook functional studies of variants and correlated these with WFS1 protein expression and phenotype.
9 patients with a clinical diagnosis of WFS were studied with quantitative PCR for markers of endoplasmic reticulum (ER) stress and immunoblotting of fibroblast protein extracts for WFS1 protein expression. Luciferase reporter assay was used to assess ATF-6 dependent unfolded protein response (UPR) activation.
6 patients with compound heterozygous nonsense mutations in had no detectable WFS1 protein expression; 3 patients with missense variants had 4%, 45% and 48% WFS1 protein expression. One of these also had an mutation and was reclassified as autosomal dominant optic atrophy-plus syndrome. There were no correlations between ER stress marker mRNA and WFS1 protein expression. ERSE-luciferase reporter indicated activation of the ATF6 branch of UPR in two patients tested. Patients with partial WFS1 expression showed milder visual acuity impairment (asymptomatic or colour blind only), compared with those with absent expression (registered severe vision impaired) (p=0.04). These differences remained after adjusting for duration of optic atrophy.
Patients with WFS who have partial WFS1 protein expression present with milder visual impairment. This suggests a protective effect of partial WFS1 protein expression on the severity and perhaps progression of vision impairment and that therapies to increase residual WFS1 protein expression may be beneficial.
Wolfram 综合征(WFS)是一种罕见的疾病,其特征为儿童期发病的糖尿病和进行性视神经萎缩。大多数患者在 基因中存在变异。我们对 变异进行了功能研究,并将这些与 WFS1 蛋白表达和表型相关联。
对 9 例临床诊断为 WFS 的患者进行了内质网(ER)应激标志物的定量 PCR 检测,并对成纤维细胞蛋白提取物进行了 WFS1 蛋白表达的免疫印迹分析。使用荧光素酶报告基因检测评估 ATF-6 依赖性未折叠蛋白反应(UPR)激活。
6 例患者携带 复合杂合无义突变,无法检测到 WFS1 蛋白表达;3 例患者携带错义变异,WFS1 蛋白表达分别为 4%、45%和 48%。其中 1 例还携带 突变,被重新归类为常染色体显性视神经萎缩加综合征。ER 应激标志物 mRNA 与 WFS1 蛋白表达之间没有相关性。ERSE-荧光素酶报告表明,在 2 例测试的患者中激活了 ATF6 分支的 UPR。具有部分 WFS1 表达的患者与无表达的患者(登记为严重视力受损)相比,视力损害程度较轻(仅无症状或色盲)(p=0.04)。在调整视神经萎缩持续时间后,这些差异仍然存在。
具有部分 WFS1 蛋白表达的 WFS 患者表现出较轻的视力损害。这表明部分 WFS1 蛋白表达对视力损害的严重程度和进展有保护作用,并且增加残余 WFS1 蛋白表达的治疗可能是有益的。